Abstract: A kit for reduction of blood components in a blood-related medium (12) is disclosed, wherein it comprises a gel bead container (1) containing gel beads (2) and provided with an outlet tube (3), a drip chamber (4) provided with an inlet tube (5) and an outlet tube (6), a collection container (10) provided with an inlet tube (11), and a medium container (13) adapted to contain a blood-related medium (12) and provided with an outlet tube (15), wherein the outlet tube (3) of the gel bead container (1) is connectable with the inlet tube (5) of the drip chamber (4) via a sterile connecting device, wherein the outlet tube (6) of the drip chamber is connectable with the inlet tube (11) of the collection container (10) via a sterile connecting device, and wherein the outlet tube (15) of the medium container (13) is connectable to the inlet tube (5) of the drip chamber (4) via a sterile connecting device, as well as a method for reduction of blood components in a blood-related medium (12) by use of said kit.

Abstract: An adsorbent comprising at least two types of covalently bound antigens having the ability to bind at least one component present in a blood flow or blood plasma flow passing through said adsorbent is disclosed, as well as a column containing said adsorbent, a kit containing said column in a sealed plastic bag, a method for the production of said kit, a method for reduction or elimination of undesired blood group specific antibodies or autoimmune antibodies in connection with autoimmune diseases, a method for treatment of myasthenia gravis, and a method for treatment of rheumatoid arthritis.

Abstract: A protein-binding product comprising one or more porous polymer beads, wherein at least one ligand is bound to the surfaces of said polymer beads via a spacer (R), and wherein said at least one ligand is Gal?1-3HexNAc?—O—, Gal?1-4GlcNAc?—O— and/or a derivative thereof, is disclosed as well as a device containing said protein-binding product and a method for reduction of the level of at least one galactose-binding protein and optionally at least one other protein in human blood plasma.

Abstract: Apparatus for contacting body fluids with the bio-affinity material is disclosed. The apparatus includes a container having top and bottom lock covers that clip onto the container.

Abstract: Apparatus for contacting body fluids with the bio-affinity material is disclosed. The apparatus includes a container having top and bottom lock covers that clip onto the container.

Abstract: A method for the detection of at least one analyte in a sample is disclosed, wherein it comprises the steps of: a) providing a layer comprising a porous matrix having at least one ligand bound thereto above a filter constituting the bottom of at least one well of an assay plate, wherein said filter does not allow passage of said porous matrix having a ligand bound thereto, b) adding a sample containing said at least one analyte to be detected, said at least one analyte having the ability to specifically bind to said at least one ligand, c) adding a wash solution with a view to washing out non-bound sample components from the assay plate through the filter, d) adding enzyme-linked antibodies or antigens having the ability to specifically bind to said at least one analyte, e) adding a wash solution with a view to washing out non-bound enzyme-linked antibodies or antigens from the analysis plate through the filter, f) adding a substrate specific for the enzyme, wherein a product is formed by a reaction between t

Abstract: A method for the reduction or elimination of one or more components from a blood product or a fluid is disclosed. The method comprises continuous addition of the blood product to a filter containing an inlet and an outlet for the blood product in which one or more components have been reduced or eliminated. Hollow fiber membranes are arranged with a space between them and with pores through which one or more components and a blood plasma pass outwardly. A loop is arranged between a blood plasma inlet and an outlet. The space between hollow fibers and the loop contains an adsorbent which specifically binds one or more components. Pores of the hollow fibers do not allow passage of the adsorbent into the hollow fiber membranes and the blood plasma is continuously recirculated via the loop back to the space between the hollow fibers. The addition of blood product is stopped when the concentration of one or more components which exits the filter via the outlet reaches a predetermined value.

Abstract: A method for extracorporeal elimination of one or more components from blood where whole blood or blood plasma is added to a blood treatment device containing an adsorbent which binds the one or more components is disclosed. The adsorbent comprises at least one matrix to which at least one ligand having specific binding affinity to said one or more component is covalently bound. The ligand comprises a glycosidically bound aglycon and at least one saccharide, preferably blood group determinant A, blood group determinant B, blood group H determinant, a P antigen, or a Pk antigen; or said ligand is an amino acid, a peptide or an antibody. Methods for treatment of transplant recipients, and to use a blood treatment device is also disclosed.

Abstract: The present invention describes product and analysis method for analysis of a substance, a virus, a bacteria or a cell which binds to carbohydrate structures. One or more carbohydrates, or carbohydrate derivatives, is bound to spherical or non-spherical polymer beads (for example microspheres or nanospheres). Formed carbohydrate-polymer beads or carbohydrate-polymer particles, can bind to with more or less specific affinity to the substance, bacteria, virus or cell which shall be detected. The carbohydrate beads is contacted with a sample containing the substance, bacteria, virus or cell (completely or partially isolated, or not purified, in a non-diluted or diluted solution). The resulting mixture is optionally added to a gel, or a column containing a gel, through which the resulting mixture (of carbohydrate beads or carbohydrate particles bound to the substance, virus, bacteria or cell), is allowed to migrate. Detection of aggregates is made visually or using apparatus for detection.

Abstract: Material characterized by that the material contains at least one biologically active di- or trisaccharide or higher oligosaccharide which is covalently bound via a spacer to cross-linked agarose.

Abstract: A biosensor in which a carbohydrate or a derivative of a carbohydrate is used to generate a detectable signal by way of the specific binding to a protein, a virus or a cell.

Abstract: Apparatus for contacting body fluids with the bio-affinity material is disclosed. The apparatus includes a container having top and bottom lock covers that clip onto the container.

Abstract: A biosensor in which a carbohydrate or a derivative of a carbohydrate is used to generate a detectable signal by way of the specific binding to a protein, a virus or a cell.

Abstract: A biosensor in which a carbohydrate or a derivative of a carbohydrate is used to generate a detectable signal by way of the specific binding to a protein, a virus or a cell.

Abstract: Bio-affinity material containing at least one biologically active saccharide which is covalently bound via at least one spacer to a cross-linked matrix and that the material is autoclaved. Apparatus for contacting body fluids with the bio-affinity material is disclosed.

Abstract: The present invention refers to a biosensor in which an immobolized carbohydrate or a derivative thereof is used to generate a detectable signal when a protein, a virus or a cell is bound to the carbohydrate surface. The sensor is an optical sensor, a piezoelectric sensor, an electrochemical electrode or a thermistor. A method of binding carbohydrates to a gold surface is also described.

Abstract: A biosensor in which a carbohydrate or a derivative of a carbohydrate is used to generate a detectable signal by way of the specific binding to a protein, a virus or a cell.

Abstract: Material characterized by that the material contains at least one biologically active di- or trisaccharide or higher oligosaccharide which is covalently bound via a spacer to cross-linked agarose.

Abstract: Disclosed is a method of producing a compound with &bgr;1-4 linkage which contains the lactosamine structure involving reacting at least one donor substance Gal&bgr;OR where R is an organic group, and at least one acceptor substance which is a glucopyranosamino derivative having the formula GlcNR″-R′″, wherein NR″ is an azido, 2-N-acetyl-, 2-N-phtalimido, or an organic group bound to the 2-N-group of glucosamine, wherein R′″ is a glycosidically bound fluoro or is an O-, C-, N- or S-glycosidically bound aliphatic or aromatic compound, with the proviso that if NR″ is NRAc then R′″ is not OH and if NR″ is not NHAc then R′″ may be OH, in the presence of Bullera singularis or an E.C. group 3.2 glycosidase of essentially the same structure as an E.C. Group 3.2 glycosidase obtained from Bullera singularis to form the lactosamine derivative; and optionally isolating the compound with &bgr;1-4 linkage which contains the lactosamine structure.

Abstract: The present invention relates to simplified synthesis, new carbohydrate-based products and practical use of different carbohydrate-based products. Examples of these are (Gal?1-3Gal), GlcNAc?1-3Gal, ?- or ?-glycosides thereof, Gal?1-3Gal- containing tri-, or higher oligosaccharides, ?- or ?-glycosides thereof, GlcNAc?1-3Gal containing tri-, tetra-, or higher oligosaccharides, and derivatives and/or ?- or ?-glycosides thereof, Gal?1-3GalGlcNAc?1-3Gal, ?- or ?-glycosides thereof, Gal?1-3Gal?1-4GlcNAc?1-3Gal?1-4Glc, or other higher oligosaccharides containing the Gal?1-3Gal-structure, ?- or ?-glycosides thereof, modified carbohydrates, di-, tri-, oligo-, or polyfunctional products containing carbohydrate structures, and the use of the products for synthesis, affinity purification, diagnostic applications and therapy.